article · International Dental Journal
BACKGROUND: Oral lichen planus (OLP), oral lichenoid lesions (OLL), and squamous cell carcinoma on a lichenoid background (SCC-over-LP/LLP) overlap clinically, delaying malignant transformation recognition. OBJECTIVE: To evaluate a multimodal large language model (ChatGPT-5) against oral medicine (OM) specialists for tripartite classification (OLP/OLL/SCC-over-LP/LLP) and malignant-risk flagging. METHODS: Cross-sectional, paired diagnostic accuracy study adhering to STARD/STARD-AI. Retrospective, anonymized cases (n = 262; OLP = 100, OLL = 100, SCC-over-LP/LLP = 62) were independently evaluated by ChatGPT-5 and a comparator panel of board-certified OM specialists using identical clinical histories and intraoral photographs (no histopathology provided to either). A separate reference standard panel (three OM experts) established the diagnosis using full clinical data and histopathology prior to index testing. PRIMARY OUTCOME: paired accuracy (McNemar). Secondary: certainty (1-5), management agreement (Gwet's AC1), and recognition of malignant red-flag features. RESULTS: Overall accuracy was comparable (84.7% ChatGPT-5 vs 85.5% OM specialists; McNemar P = .856, Cohen's h = 0.03). Sensitivity was high for OLP 0.99 and SCC-over-LP/LLP 0.85; OLL sensitivity 0.70 with specificity 1.00. Biopsy/referral agreement was near-perfect (AC1 = 0.91). Malignant-risk features were correctly identified in 88% of SCC-over-LP/LLP cases by ChatGPT-5 vs 92% by OM specialists (P = .41). CONCLUSIONS: A multimodal large language model can reach expert-level accuracy for OLP/OLL/SCC-over-LP/LLP and reliably flag malignant transformation risk, supporting its role as an adjunctive decision-support tool in OM.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.identj.2025.109357
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.